This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
==== 4.C Acyl CoA ligase-coupled transporters ==== 4.C.1 The Proposed Fatty Acid Transporter (FAT) Family 4.C.2 The Carnitine O-Acyl Transferase (CrAT) Family 4.C.3 The Acyl-CoA Thioesterase (AcoT) Family
=== Available forms === Ciclosporin exhibits very poor solubility in water, and, as a consequence, suspension and emulsion forms of the medication have been developed for oral administration and for injection. Ciclosporin was originally brought to market by Sandoz (now Novartis), under the brand name Sandimmune, which is available as soft gelatin capsules, an oral solution, and a formulation for intravenous administration. These are all nonaqueous compositions. A newer microemulsion, orally-administered formulation, Neoral, is available as a solution and as soft gelatin capsules. Compositions of Neoral are designed to form microemulsions in contact with water. Generic ciclosporin preparations have been marketed under various brand names, including Cicloral (by Sandoz/Hexal), Gengraf (by Abbott) and Deximune (by Dexcel Pharma). Since 2002, a topical emulsion of ciclosporin for treating inflammation caused by keratoconjunctivitis sicca (dry eye syndrome) has been marketed under the brand name Restasis. Ikervis is a similar formulation with a concentration of 0.1%. Inhaled ciclosporin formulations are in clinical development, and include a solution in propylene glycol and liposome dispersions.
== Pharmacology == Akuammine has antimalarial activity, and may be the primary constituent of P. nitida seeds responsible for this activity. Akuammine is an opioid agonist with low affinity, selective for the mu-opioid receptor, when tested in vitro.
Sources: en.wikipedia.org
1993/764) Value Added Tax (Increase of Consideration for Fuel) Order 1993 (S.I. 1993/765) Value Added Tax (Increase of Registration Limits) Order 1993 (S.I. 1993/766) Value Added Tax (Protective Boots and Helmets) Order 1993 (S.I. 1993/767) Registered Establishments (Fees) (Scotland) Order 1993 (S.I. 1993/768) Act of Sederunt (Interest in Sheriff Court Decrees and Extracts) 1993 (S.I. 1993/769) Act of Sederunt (Rules of the Court of Session Amendment) (Interest in Decrees and Extracts) 1993 (S.I. 1993/770) Water Undertakers (Rateable Values) (Amendment) Order 1993 (S.I. 1993/772) Council Tax (Administration and Enforcement) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/773) Non-Domestic Rating (Collection and Enforcement) (Amendment and Miscellaneous Provision) Regulations 1993 (S.I. 1993/774) Community Charges (Administration and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/775) Pensions Increase (Review) Order 1993 (S.I. 1993/779) British Railways (Penalty Fares) Act 1989 (Activating No. 9) Order 1993 (S.I. 1993/780) British Railways (Penalty Fares) Act 1989 (Activating No. 10) Order 1993 (S.I. 1993/781) Premium Savings Bonds (Amendment) Regulations 1993 (S.I. 1993/782) National Savings Stock Register (Amendment) Regulations 1993 (S.I. 1993/783) Redundancy Payments (Local Government) (Modification) (Amendment) Order 1993 (S.I. 1993/784) Child Support Act 1991 (Consequential Amendments) Order 1993 (S.I. 1993/785) Chester Port Health Authority (Revocation)Order 1993 (S.I. 1993/786) Civil Legal Aid (Assessment of Resources) (Amendment) Regulations 1993 (S.I.
=== Tanning === Potassium alum is used in leather tanning, in order to remove moisture from the hide and prevent rotting. Unlike tannic acid, alum doesn't bind to the hide and can be washed out of it.
=== Many mobile DNA elements use an RNA intermediate === Transposable genetic elements (transposons) are found which can replicate via transcription into an RNA intermediate which is subsequently converted to DNA by reverse transcriptase. These sequences, many of which are likely related to retroviruses, constitute much of the DNA of the eukaryotic nucleus, especially so in plants. Genomic sequencing shows that retrotransposons make up 36% of the human genome and over half of the genome of major cereal crops (wheat and maize).
As the continental plates moved closer together, fragments of oceanic crust, islands, and other continental masses collided with the eastern margin of ancestral North America. By this time, plants had appeared on land, followed by scorpions, insects, and amphibians. The ocean continued to shrink until, about 270 million years ago, the continents that were ancestral to North America and Africa collided during the formation of the supercontinent Pangea. Because North America and Africa were once geographically connected, the Appalachians formed part of the same mountain chain as the Little Atlas in Morocco. This mountain range, known as the Central Pangean Mountains, extended into Scotland, before the Mesozoic Era opening of the Iapetus Ocean, from the North America/Europe collision (See Caledonian orogeny). By the end of the Mesozoic Era, the Appalachian Mountains had been eroded to an almost flat plain. It was not until the region was uplifted during the Cenozoic Era that the distinctive topography of the present formed. Uplift rejuvenated the streams, which rapidly responded by cutting downward into the ancient bedrock. Some streams flowed along weak layers that define the folds and faults created many millions of years earlier. Other streams downcut so rapidly that they cut right across the resistant folded rocks of the mountain core, carving canyons across rock layers and geologic structures.
Sources: en.wikipedia.org
HITS-CLIP (High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation or CLIP-seq) PAR-CLIP (Photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation) iCLIP (Individual nucleotide-resolution cross-linking and immunoprecipitation) eCLIP (Enhanced cross-linking and immunoprecipitation followed by high-throughput sequencing) sCLIP (Simple cross-linking and immunoprecipitation)
The Port of Hong Kong, located by the South China Sea, is a deepwater seaport dominated by trade in containerised manufactured products. A key factor in the economic development of Hong Kong, the natural shelter and deep waters of Victoria Harbour provide ideal conditions for berthing and the handling of all types of vessels. It is one of the busiest ports in the world, in the three categories of shipping movements, cargo handled, and passengers carried. This makes Hong Kong a Large-Port Metropolis. The Star Ferry operates two lines across Victoria Harbour for its 53,000 daily passengers. Ferries also serve outlying islands inaccessible by other means. Smaller kai-to boats serve the most remote coastal settlements. Ferry travel to Macau and mainland China is also available. Junks, once common in Hong Kong waters, are no longer widely available and are used privately and for tourism. The large size of the port gives Hong Kong the classification of Large-Port Metropolis.
== Combination hemoglobinopathies == A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. If these are different versions of the same gene, one having been inherited from each parent it is an example of compound heterozygosity. Some examples of clinically significant combinations involving beta thalassemia include:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.